Tower Research Capital (TRC)’s RenovoRx RNXT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.14K Sell
1,161
-5,051
-81% -$4.59K ﹤0.01% 4882
2026
Q1
$6.27K Sell
6,212
-150
-2% -$145 ﹤0.01% 4066
2025
Q4
$5.34K Buy
6,362
+4,773
+300% +$4.78K ﹤0.01% 4133
2025
Q3
$2.02K Buy
+1,589
New +$1.89K ﹤0.01% 4697
2025
Q2
Sell
-3,683
Closed -$3.65K 5526
2025
Q1
$3.65K Buy
3,683
+2,866
+351% +$3.33K ﹤0.01% 4373
2024
Q4
$1.05K Sell
817
-3,253
-80% -$3.7K ﹤0.01% 5105
2024
Q3
$4.31K Sell
4,070
-3,319
-45% -$3.72K ﹤0.01% 4590
2024
Q2
$8.35K Buy
7,389
+1,120
+18% +$1.38K ﹤0.01% 4363
2024
Q1
$8.4K Buy
6,269
+1,670
+36% +$2.41K ﹤0.01% 4026
2023
Q4
$10.5K Buy
4,599
+2,390
+108% +$2.28K ﹤0.01% 4234
2023
Q3
$2.94K Sell
2,209
-6,512
-75% -$11.7K ﹤0.01% 5082
2023
Q2
$19.7K Buy
8,721
+5,120
+142% +$12.4K ﹤0.01% 3401
2023
Q1
$13K Sell
3,601
-515
-13% -$1.81K ﹤0.01% 4003
2022
Q4
$10K Sell
4,116
-378
-8% -$722 ﹤0.01% 4062
2022
Q3
$9K Buy
4,494
+1,813
+68% +$3.94K ﹤0.01% 4684
2022
Q2
$5K Sell
2,681
-395
-13% -$807 ﹤0.01% 5091
2022
Q1
$9K Buy
3,076
+2,185
+245% +$7.65K ﹤0.01% 4484
2021
Q4
$4K Sell
891
-4,821
-84% -$28.6K ﹤0.01% 5337
2021
Q3
$35K Buy
+5,712
New +$47.6K ﹤0.01% 3245

Other funds holding RNXT

Tower Research Capital (TRC)'s RNXT Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its RenovoRx (RNXT) stake by 81% in Q2 2026, selling an estimated $4.59K and leaving 1,161 shares worth $1.14K. The position accounts for ﹤0.01% of the portfolio, ranked #4882.

Tower Research Capital (TRC) first reported a position in RNXT in Q3 2021 and has held it in 19 quarters since. The position peaked at $35K in Q3 2021. 28 funds tracked by Wall St. Rank hold RNXT as of Q2 2026.

  • Tower Research Capital (TRC) held 1,161 shares of RenovoRx worth $1.14K as of Q2 2026.
  • Tower Research Capital (TRC) sold 5,051 RenovoRx shares in Q2 2026, an estimated $4.59K.
  • RenovoRx made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4882 holding.
  • Tower Research Capital (TRC) first reported a position in RenovoRx in Q3 2021 and has held it in 19 quarters since.
  • Tower Research Capital (TRC)'s RenovoRx position peaked at $35K in Q3 2021.
  • 28 funds tracked by Wall St. Rank held RenovoRx as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.